Spots Global Cancer Trial Database for Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Official Title: An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple Myeloma
Study ID: NCT05227144
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options
Detailed Description: ORIC-533 is a selective, orally bioavailable, small molecule inhibitor of CD73.This is an open-label, uncontrolled, multicenter, dose-finding study to assess the safety and preliminary antimyeloma activity of ORIC-533 in patients with relapsed or refractory multiple myeloma. After the RP2D has been determined, dose expansion will further evaluate safety and preliminary antimyeloma activity of ORIC-533 in patients with relapsed or refractory multiple myeloma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
James R. Berenson, MD, Inc., West Hollywood, California, United States
Northside Hospital Cancer Institute, Atlanta, Georgia, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinical Rochester, Rochester, Minnesota, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health, Charlotte, North Carolina, United States
Swedish Health Services, Seattle, Washington, United States
Princess Margaret Cancer Research Center/University Health Network, Toronto, Ontario, Canada
Contact Details
Name: Pratik S. Multani, MD
Affiliation: ORIC Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
